NCT04081688 2026-02-05
Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC
Rutgers, The State University of New Jersey
Phase 1 Terminated
Clinical Trials
10 trialsNCT03038672 2025-11-10
Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04941287 2025-05-23
Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03688178 2025-04-15
DERIVe
Duke University
Phase 2 Active not recruiting
NCT03307746 2024-12-02
RiVa
University Hospital Southampton NHS Foundation Trust
Phase 1/2 Completed
NCT02924038 2024-06-14
A Study of Varlilumab and IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG)
University of California, San Francisco
Phase 1 Terminated
NCT03617328 2024-02-06
Mel-65
University of Virginia
Phase 1/2 Completed
NCT02302339 2019-09-06
A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma
Celldex Therapeutics
Phase 2 Terminated
NCT02284971 2018-05-17
Prostate-04
University of Virginia
Phase 1 Terminated
NCT01460134 2018-01-31
A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
Celldex Therapeutics
Phase 1 Completed